Movatterモバイル変換

Retagliptin

From Wikipedia, the free encyclopedia

Chemical compound

Pharmaceutical compound

Retagliptin
Identifiers

IUPAC name Methyl 7-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(trifluoromethyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-carboxylate
CAS Number	1174122-54-3
PubChemCID	44193830
DrugBank	DB14898
ChemSpider	57583801
UNII	328C4R3P9L
ChEMBL	ChEMBL4297435
Chemical and physical data
Formula	C₁₉H₁₈F₆N₄O₃
Molar mass	464.368 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES COC(=O)C1=C2CN(CCN2C(=N1)C(F)(F)F)C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N
InChI InChI=1S/C19H18F6N4O3/c1-32-17(31)16-14-8-28(2-3-29(14)18(27-16)19(23,24)25)15(30)6-10(26)4-9-5-12(21)13(22)7-11(9)20/h5,7,10H,2-4,6,8,26H2,1H3/t10-/m1/s1 Key:WIIAMRXFUJLYEF-SNVBAGLBSA-N

Retagliptin is aDPP-4 inhibitor studied for the treatment of type 2 diabetes.^[1]^[2]^[3]

In 2023, it was approved in China by theNational Medical Products Administration for blood glucose control for adult patients withtype 2 diabetes.^[4]

^Meng, Xiangjun; Cai, Lanlan; Ren, Tianming; Sun, Dong; Gu, Jingkai (2018)."Simultaneous quantitative analysis of retagliptin and its main active metabolite in human multiple matrices by liquid chromatography tandem mass spectrometry".Analytical Methods.10 (18):2108–2114.doi:10.1039/C8AY00040A.ISSN 1759-9679.
^Hu, Chao; Zheng, Jing; Miao, Jia; Liu, Fang; Hu, Ting-Ting; Gu, Jing-Kai; Shu, Shi-Qing; Wang, Ying; Zhu, Xiao-Hong; Liang, Mao-Zhi (2018)."[Pharmacokinetics of Phosphate Retagliptin Tabletin in Patients with Renal Dysfunction]".Sichuan da Xue Xue Bao. Yi Xue Ban = Journal of Sichuan University. Medical Science Edition.49 (1):74–80.ISSN 1672-173X.PMID 29737094.
^Cahn, Avivit; Cernea, Simona; Raz, Itamar (2016). "An update on DPP-4 inhibitors in the management of type 2 diabetes".Expert Opinion on Emerging Drugs.21 (4):409–419.doi:10.1080/14728214.2016.1257608.PMID 27809608.S2CID 45825587.
^"Retagliptin Phosphate Tablets Approved for Marketing by NMPA". National Medical Products Administration. 2023-06-28.

fast-acting	Insulin aspart Insulin glulisine Insulin lispro
short-acting	Regular insulin^#
long-acting	Insulin detemir^# Insulin glargine^# (+lixisenatide) NPH insulin Lente insulin^‡ Ultralente insulin^‡
ultra-long-acting	Insulin degludec^# (+insulin aspart,+liraglutide) Insulin icodec^† (+semaglutide)
inhalable	Exubera^‡ Afrezza
Oral	Insulin tregopil^†

Non-insulins

Biguanides	Buformin^‡ Metformin^# Phenformin^‡
TZDs/"glitazones" (PPAR)	Ciglitazone^§ Darglitazone^§ Englitazone^§ Lobeglitazone Netoglitazone^§ Pioglitazone Rivoglitazone^† Rosiglitazone Troglitazone^‡
Dual PPAR agonists	Aleglitazar^† Muraglitazar^§ Saroglitazar Tesaglitazar^§
Amylin analogues andDACRAs	Cagrilintide^§ Pramlintide

Sulfonylureas	1st generation:Acetohexamide Carbutamide Chlorpropamide Glycyclamide Metahexamide Tolazamide Tolbutamide 2nd generation:Glibenclamide (glyburide) Glibornuride Glicaramide Gliclazide^# Glimepiride Glipizide Gliquidone Glisoxepide Glyclopyramide
Meglitinides/"glinides"	Mitiglinide Nateglinide Repaglinide

GLP1 poly-agonist peptides	Mazdutide (GLP-1/GCGR) Retatrutide^§ (GLP-1/GIP/GCGR) Tirzepatide (GLP-1/GIP)

Other

Aldose reductase inhibitors	Epalrestat Fidarestat^§ Ranirestat^† Tolrestat^‡ Zenarestat^§
Alpha-glucosidase inhibitors	Acarbose Miglitol Voglibose
SGLT2 inhibitors/"gliflozins"	Canagliflozin Dapagliflozin Empagliflozin^# Ertugliflozin Ipragliflozin Luseogliflozin Remogliflozin^§ Sergliflozin^§ Sotagliflozin Tofogliflozin^† Velagliflozin
Other	Benfluorex^‡ Bromocriptine Imeglimin

Hidden categories: